Baidu
map

Thorax:COVID-19患者动静脉血栓栓塞患病率分析

2021-03-27 MedSci原创 MedSci原创

因严重COVID-19入住ICU的患者发生VTE的风险较高。

COVID-19患者静脉血栓栓塞事件(VTE)和动脉血栓栓塞事件(ATE)的发生率仍是未知的。

近日,胸部疾病领域权威杂志Thorax上发表了一篇研究文章,研究人员系统地检索了评估COVID-2019患者VTE和ATE患病率的观察性研究,检索时间截至2020年9月30日。

研究人员分析了102项研究(64503位患者)的结果。与COVID-19相关的VTE发生率为14.7%(95%CI为12.1%至17.6%,I2=94%;56项研究;16507名患者)。肺栓塞(PE)和腿部深静脉血栓形成的总体患病率分别为7.8%(95%CI为6.2%至9.4%,I2=94%;66项研究;23117名患者)和11.2%(95%CI为8.4%至14.3%,I2=95%;48项研究;13824名患者)。很少有孤立性亚节段性PE。

重症监护病房(ICU)患者的VTE患病率更高(23.2%,95%CI为17.5%至29.6%,I2=92%,vs. 9.0%,95%CI为6.9%至11.4%,I2=95%;P<0.0001)。总体ATE、急性冠脉综合征卒中和其他ATE的发生率分别为3.9%(95%CI为2.0%至3.0%,I2=96%; 16项研究;7939例患者)、1.6%(95%CI为1.0%至2.2%,I2=93%;27项研究;40597名患者)和0.9%(95%CI为0.5%至1.5%,I2=84%;17项研究;20139名患者)。Meta回归和亚组分析未能解释整个ATE的异质性。高度异质性限制了评估的价值。

由此可见,因严重COVID-19入住ICU的患者发生VTE的风险较高

原始出处:

Boun Kim Tan,et al.Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis.Thorax.2021.https://thorax.bmj.com/content/early/2021/03/24/thoraxjnl-2020-215383

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1698203, encodeId=7c7c16982034a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jul 17 23:48:38 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955532, encodeId=a2381955532d7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 04 09:48:38 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250731, encodeId=3ad41250e31b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297522, encodeId=9518129e522ee, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951819, encodeId=f5dc9518193a, content=我学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 10:04:36 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
    2021-07-17 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1698203, encodeId=7c7c16982034a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jul 17 23:48:38 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955532, encodeId=a2381955532d7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 04 09:48:38 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250731, encodeId=3ad41250e31b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297522, encodeId=9518129e522ee, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951819, encodeId=f5dc9518193a, content=我学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 10:04:36 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
    2021-11-04 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1698203, encodeId=7c7c16982034a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jul 17 23:48:38 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955532, encodeId=a2381955532d7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 04 09:48:38 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250731, encodeId=3ad41250e31b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297522, encodeId=9518129e522ee, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951819, encodeId=f5dc9518193a, content=我学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 10:04:36 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1698203, encodeId=7c7c16982034a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jul 17 23:48:38 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955532, encodeId=a2381955532d7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 04 09:48:38 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250731, encodeId=3ad41250e31b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297522, encodeId=9518129e522ee, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951819, encodeId=f5dc9518193a, content=我学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 10:04:36 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1698203, encodeId=7c7c16982034a, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Jul 17 23:48:38 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955532, encodeId=a2381955532d7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 04 09:48:38 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250731, encodeId=3ad41250e31b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297522, encodeId=9518129e522ee, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Mar 29 01:48:38 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=951819, encodeId=f5dc9518193a, content=我学到了很多东西谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5b3006368, createdName=1436749007, createdTime=Sun Mar 28 10:04:36 CST 2021, time=2021-03-28, status=1, ipAttribution=)]
    2021-03-28 1436749007

    我学到了很多东西谢谢老师

    0

相关资讯

Gastroenterology:胰腺导管腺癌需警惕静脉血栓的发生

胰腺导管腺癌断后静脉血栓栓塞早期发作或频发导致患者预后较差,需要进行研究以确定PDAC患者的VTE初级预防是否会改善与VTE相关的发病率和死亡率

Blood:静脉血栓栓塞(VTE)和出血评估模型所忽视的预测因素

中心点:通过系统方法,本研究确定了23个静脉血栓栓塞和15个出血的预后因素。这些因素在大多数广泛使用的风险评估模型中均没有被纳入考虑。摘要:可能存在许多住院患者静脉血栓栓塞(VTE)和出血的预测因素,但迄今为止,还没有系统研究和评估证据。Darzi等人开展了一项系统回顾,从开始到2018年5月,检索Medline和EMBASE,以明确住院患者VTE和出血的预后因素。审查员独立提取重复的数据,并使用

Blood:全外显子测序明确STAB2罕见变异与VTE密切相关

深静脉血栓形成和肺栓塞,统称为静脉血栓栓塞(VTE),是美国心血管疾病死亡的第三大原因。全基因组关联研究(GWAS)已经确认了导致不同程度静脉血栓栓塞风险增加的常见遗传变异。抗凝基因PROC、PROS

Circulation:PCSK9抑制对静脉血栓栓塞(VTE)风险的影响

胆固醇水平与静脉血栓栓塞(VTE)风险之间的关系尚不确定。本研究旨在探索PCSK9( 9型前蛋白转化酶枯草杆菌蛋白酶/ kexin)抑制作用对VTE风险的影响及其潜在机制,并评估PCSK9抑制在具有临

Blood:新冠病毒感染者的出血和血栓栓塞风险及预测标志物

新冠病毒(COVID-19)患者的D-二聚体水平升高。早期报道提示新冠病毒感染患者有较高的静脉血栓栓塞(VTE)和弥散性血管内凝血(DIC)的概率,但无明确数据。

J Thromb Haemost:苯二氮卓受体激动剂与静脉血栓栓塞风险

前使用BZRA可能会增加VTE的风险。同样,苯二氮卓类催眠药,尤其是氟硝西泮,具有较高的VTE风险。

Baidu
map
Baidu
map
Baidu
map